OBI Pharma Cash Flow Conversion Efficiency

Latest as of June 2026: -0.132x

OBI Pharma cash flow conversion efficiency. Based on the latest financial reports, OBI Pharma (4174) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-290.40 Million ≈ $-9.15 Million USD) by net assets (NT$2.19 Billion ≈ $69.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of OBI Pharma (2011–2025)

Cash flow conversion efficiency of OBI Pharma from 2011 to 2025. This chart illustrates how OBI Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 4174 stock price for real-time trading data and today's change.

OBI Pharma Cash Flow Conversion Ratio Explained

OBI Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

OBI Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of OBI Pharma ranked by their cash flow conversion efficiency. Also see OBI Pharma (4174) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Platinum Analytics Cayman Limited Class A Ordinary Shares NASDAQ:PLTS	-1.055x
KlaraBo Sverige AB Series B ST:KLARA-B	0.001x
Kobay Tech Bhd KLSE:6971	0.071x
PERPETUAL EQU. INV. F:P82	N/A
Major Cineplex Group Public Company Limited BK:MAJOR-R	0.105x
AVE Science & Technology Co Ltd SHG:688067	0.029x
Cathay Chemical Works Inc TW:1713	0.062x
Samsung C and T 1P Pref KO:02826K	0.026x

Annual Cash Flow Conversion Efficiency for OBI Pharma (2011–2025)

The table below shows the annual cash flow conversion efficiency of OBI Pharma from 2011 to 2025. Review OBI Pharma free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$2.73 Billion ≈ $85.86 Million	NT$-2.02 Billion ≈ $-63.65 Million	-0.741x	-94.89%
2024-12-31	NT$4.82 Billion ≈ $151.87 Million	NT$-1.83 Billion ≈ $-57.77 Million	-0.380x	-13.99%
2023-12-31	NT$4.95 Billion ≈ $156.06 Million	NT$-1.65 Billion ≈ $-52.08 Million	-0.334x	-26.42%
2022-12-31	NT$6.14 Billion ≈ $193.32 Million	NT$-1.62 Billion ≈ $-51.03 Million	-0.264x	+4.01%
2021-12-31	NT$3.87 Billion ≈ $121.95 Million	NT$-1.06 Billion ≈ $-33.54 Million	-0.275x	+17.34%
2020-12-31	NT$4.84 Billion ≈ $152.42 Million	NT$-1.61 Billion ≈ $-50.71 Million	-0.333x	-65.38%
2019-12-31	NT$5.20 Billion ≈ $163.96 Million	NT$-1.05 Billion ≈ $-32.98 Million	-0.201x	-4.12%
2018-12-31	NT$4.47 Billion ≈ $140.94 Million	NT$-864.31 Million ≈ $-27.23 Million	-0.193x	+11.67%
2017-12-31	NT$5.06 Billion ≈ $159.43 Million	NT$-1.11 Billion ≈ $-34.87 Million	-0.219x	-60.41%
2016-12-31	NT$6.16 Billion ≈ $194.10 Million	NT$-840.10 Million ≈ $-26.47 Million	-0.136x	-163.20%
2015-12-31	NT$7.18 Billion ≈ $226.34 Million	NT$-372.20 Million ≈ $-11.73 Million	-0.052x	+83.89%
2014-12-31	NT$1.44 Billion ≈ $45.49 Million	NT$-464.22 Million ≈ $-14.63 Million	-0.322x	-495.51%
2013-12-31	NT$1.93 Billion ≈ $60.78 Million	NT$-104.16 Million ≈ $-3.28 Million	-0.054x	+61.92%
2012-12-31	NT$829.77 Million ≈ $26.14 Million	NT$-117.64 Million ≈ $-3.71 Million	-0.142x	+85.82%
2011-12-31	NT$508.44 Million ≈ $16.02 Million	NT$-508.22 Million ≈ $-16.01 Million	-1.000x	--

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$196.08 Million

NT$6.22 Billion TWD

Market Cap Rank

#16415 Global

#785 in Taiwan

Share Price

NT$47.30

Change (1 day)

+0.42%

52-Week Range

NT$23.25 - NT$59.90

All Time High

NT$743.00